Persistence of Lyme Disease Despite Antibiotic Treatment

77 Peer-Reviewed Studies, 1977-2012

“These results demonstrate that *B. burgdorferi* can withstand antibiotic treatment, administered post-dissemination, in a primate host.”
Persistence of *Borrelia burgdorferi* in rhesus macaques following antibiotic treatment of disseminated infection.

“[Our] results challenge prevailing dogma about [the] effectiveness of antibiotics for eliminating *B. burgdorferi* infection... spirochetes persisted in sites where they encountered the antibiotic.”

Ineffectiveness of Tigecycline against *Borrelia burgdorferi*.
Barthold SW, Hodzic E, Imai D, Feng S, Yang X, Luft B.J.
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Title</th>
<th>Journal</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Embers ME; Barthold SW; Borda JT; Bowers L; Doyle L; Hodzic E; Jacobs MG; Hasenkampf NR; Martin DS; Narasimhan S; Philipp-Falkenstein KM; Purcell JE; Ratterree MS; Philipp MT.</td>
<td>2012</td>
<td>Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection.</td>
<td>PLoS One, 7(1):e29914</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[From the abstract:] &quot;B. burgdorferi antigen, DNA and RNA were detected in the tissues of treated animals. Finally, small numbers of intact spirochetes were recovered by xenodiagnosis from treated monkeys. These results demonstrate that B. burgdorferi can withstand antibiotic treatment, administered post-dissemination, in a primate host.&quot;</td>
<td>[From the article:] &quot;Our results indicate that disseminated spirochetes of two different B. burgdorferi strains can persist in the primate host following high dose, or long-lasting antibiotic therapy.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[Experiment 1: 30 days ceftriaxone followed by 60 days doxycycline. Treatment initiated 6.5 months post inoculation. Experiment 2: 28 days high dose doxycycline (12mg/kg/day). Treatment initiated 4 months post inoculation.]</td>
<td></td>
</tr>
<tr>
<td>2. Barthold SW; Hodzic E; Imai D; Feng S; Yang X; Luft BJ.</td>
<td>2010</td>
<td>Ineffectiveness of Tigecycline against persistent Borrelia burgdorferi.</td>
<td>Antimicro Agents Chemother, 54(2):643-51</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[From the abstract:] &quot;The viability of non-cultivable spirochetes in antibiotic-treatment mice (demonstrable by PCR) was confirmed by transplantation of tissue allografts from treated mice into SCID mice, with dissemination of spirochetal DNA to multiple recipient tissues, and by xenodiagnoses... PCR-positive heart base tissue from antibiotic-treated mice revealed RNA transcription of several B. burgdorferi genes. These results extended previous studies with ceftriaxone, indicating that antibiotic treatment is unable to clear persisting spirochetes, which remain viable and infectious, but are nondividing or slowly dividing.&quot;</td>
<td>[From the article:] &quot;These results challenge prevailing dogma about [the] effectiveness of antibiotics for eliminating B. burgdorferi infection, and therefore further work is critically needed. “These findings suggest that spirochetes persisted in sites where they encountered the antibiotic.” &quot;Borrelia burgdorferi has evolved to persistently infect fully immunocompetent hosts. ...Therefore, the “mop up” phase, which is dependent upon the immune system, is likely to be ineffective against an agent such as B. burgdorferi, which is highly effective at evading host clearance.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>[Mice were treated with either 30 days ceftriaxone or 10 days tigecycline. Controls were given saline.]</td>
<td></td>
</tr>
<tr>
<td>3. Yrjänäinen H; Hytönen J; Hartiala P; Oks J; Viljanen MK.</td>
<td>2010</td>
<td>Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment.</td>
<td>APMIS, 118(9):665-73</td>
</tr>
<tr>
<td></td>
<td></td>
<td>&quot;We have earlier shown that Borrelia burgdorferi-infected and ceftriaxone-treated mice have viable spirochetes in their body, since immunosuppressive treatment allows B. burgdorferi to be detected by culture. However, the niche of the persisting spirochetes remained unknown. ...[In this study], B. burgdorferi DNA was detected in the joints of 30-100% of the treated mice. In conclusion, these results combined with earlier results suggest that the joint or a tissue adjacent to the joint is the niche of persisting B. burgdorferi in ceftriaxone-treated mice.&quot;</td>
<td></td>
</tr>
</tbody>
</table>
4. James FM; 2010
Engiles JB; Beech J.
Meningitis, cranial neuritis, and radiculoneuritis associated with Borrelia burgdorferi infection in a horse.

"...results of a PCR assay of CSF for B burgdorferi DNA were positive. ...The horse responded well to doxycycline treatment ... However, 60 days after treatment was discontinued, the horse again developed a stiff neck and rapidly progressive neurologic deficits, including severe ataxia and vestibular deficits. The horse’s condition deteriorated rapidly despite IV oxytetracycline treatment, and the horse was euthanatized. Postmortem examination revealed leptomeningitis, lymphohistiocytic leptomeningeal vasculitis, cranial neuritis, and peripheral radiculoneuritis... findings were consistent with a diagnosis of neuroborreliosis."

5. Hodzic, E; 2008
Feng S; Holden K; Freet K; Barthold SW.
Persistence of Borrelia burgdorferi following antibiotic treatment in mice.

[From the abstract:] "Mice were treated with ceftriaxone or saline for one month, commencing during the early (3 weeks) or chronic (4 months) stages of infection with Borrelia burgdorferi. Tissues from mice were tested for infection by culture, polymerase chain reaction (PCR), xenodiagnosis, and transplantation of allografts at 1 and 3 months after completion of treatment. ...Results indicated that following antibiotic treatment, mice remained infected with non-dividing but infectious spirochetes, particularly when antibiotic treatment was commenced during the chronic stage of the infection."

[From the article:] "The current study indicated that accessible indices of treatment, such as culture or PCR of skin and serologic response, cannot be relied upon as markers for treatment success. A declining antibody response, which has been noted following antibiotic treatment in mice (9), as well as in antibiotic-treated dogs (61), occurs despite low levels of persisting spirochetes. Our results show that spirochetes are viable, transmissible, and express antigen (based upon immunohistochemistry) following antibiotic treatment, particularly when commenced during the late stage of the infection. However, the residual few spirochetes appear to be altered in their ability to replicate, and this may explain the lack of inflammation that we noted in SCID mouse tissues.

6. Yrjänäinen H; 2007
Hytönen J; Song XY; Oksi J; Hartiaa K; Viljanen MK.
Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.

"RESULTS: At 14 weeks of infection, B. burgdorferi could not be detected by cultivation or by polymerase chain reaction in tissue samples of any mouse treated with ceftriaxone only. However, spirochetes grew from the tissue samples of one-third of the mice treated with anti-TNF-alpha simultaneously or 4 weeks after ceftriaxone. These activated spirochetes showed ceftriaxone sensitivity rates, plasmid profiles, and virulence rates similar to those of bacteria used to infect the mice. All infected control mice and mice given anti-TNF-alpha only were culture positive. CONCLUSIONS: This report shows that, after ceftriaxone treatment for 5 days, a portion of B. burgdorferi-infected mice still have live spirochetes in their body, which are activated by anti-TNF-alpha treatment."

7. Hunfeld KP; 2005
Ruzic-Sabljic E; Norris DE; Kraiczy P; Strie F.
In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy.

[From the abstract:] “Clinical treatment failures have been reported to occur in early Lyme borreliosis (LB) for many suitable antimicrobial agents. ... Here, borrellial isolates obtained from five patients with erythema migrans (EM) before the start of antibiotic therapy and again after the conclusion of treatment were investigated. ... Our study substantiates borrelial persistence in some EM patients at the site of the infectious lesion despite antibiotic treatment over a reasonable time period. Borrelial persistence, however, was not caused by increasing MICs or minimal borreliacidal concentrations in these isolates. Therefore, resistance mechanisms other than acquired resistance to antimicrobial agents should be considered in patients with LB resistant to treatment.”
**Antibiotic treatment of experimentally Borrelia burgdorferi-infected ponies.**

*Vet Microbio, 107(3-4):285-94*

*[From the abstract:]* “Ponies experimentally infected with Borrelia burgdorferi by tick exposure were treated with doxycycline, ceftriofur or tetracycline for 4 weeks (28 days). Doxycycline and ceftriofur treatment were inconsistent in eliminating persistent infection in this experimental model. However, tetracycline treatment seems to eliminate persistent infection. Although serum antibody levels to B. burgdorferi in all ponies declined gradually after antibiotic treatment, three out of four ponies treated with doxycycline and two out of four ponies treated with ceftriofur, serum KELA titers were raised again 3 month after treatment was discontinued. Five months after antibiotic treatment, tissues aseptically collected at necropsy from ponies with increased antibody levels after antibiotic treatment also showed culture positive to B. burgdorferi in various post-mortem tissues. However, all four-tetracycline treatment ponies showed a negative antibody level and culture negative from post-mortem tissues. Untreated infected ponies maintained high KELA titers throughout the study and were tissue culture positive.”

**Long term and repeated electron microscopy and PCR detection of Borrelia burgdorferi sensu lato after an antibiotic treatment.**

*Cent Eur J Public Health, 12(1):6-11*

“*The diagnosis of Lyme disease in 18 patients has been proved by detection of Borrelia burgdorferi sensu lato when using immunoelectron microscopy or detecting its nucleic acid by PCR in the plasma or the cerebrospinal fluid. The positive results occurred in the plasma or in the cerebrospinal fluid in the period of 4-68 months after an antibiotic treatment.*”

**Isolation and polymerase chain reaction typing of Borrelia afzelii from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus.**

*Br J Derm, 144(2):387-92*

*[From the abstract:]* “Despite treatment with four courses of ceftriaxone with or without methylprednisone for up to 20 days, progression of LSA [lichen sclerosus et atrophicus] was only stopped for a maximum of 1 year. Spirochaetes were isolated from skin cultures obtained from enlarging LSA lesions. These spirochaetes were identified as Borrelia afzelii by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and polymerase chain reaction (PCR) analyses. However, serology for B. burgdorferi sensu lato was repeatedly negative.” *[From the article:]* “The relapses she repeatedly suffered despite initially successful antibiotic treatment could be related to the observation that Borrelia may possibly be able to remain dormant in certain tissue compartments, thus escaping bactericidal antibiotic activity. This would be consistent with the fact that these relapses were always able to be treated successfully with a course of the same antibiotics as before; this is corroborated by a recent report that Bb may persist in experimentally infected dogs despite antibiotic treatment with doxycycline or amoxycillin.”

**PCR-based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-day postinfection period.**

*J Clin Microbiology, 38(6):2191-99*

“*Antibiotic treatment resulted in the temporary disappearance of B. burgdorferi DNA. Skin samples became positive by PCR starting 60 days after treatment had ended, and additional positive samples were detected later. ...therapy with different antibiotics seems to reduce the load of B. burgdorferi infection to a level of approximately 53 to 13,078 spirochetes per 100 µg of extracted total DNA but fails to eliminate the infection. [Dogs were treated with ceftriaxone, doxycycline, or azithromycin for 30 consecutive days.] After antibiotic therapy had ended, in some treated dogs antibody titers remained at constant levels rather than decreasing further. This argues more for the persistence of the antigenic stimulus than for the complete elimination of B. burgdorferi.*” *

*[Diagnosis:]* “…DNA of heat-killed borrelia was not detectable for very long in skin tissue of an uninfected dog, implying that during natural infection the DNA of killed organisms is removed quickly and completely within a few days.”
12. Straubinger RK; Straubinger AF; Jacobson RH.  
**Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study.**

J Infect Dis, 181(3):1069-81

16 dogs were infected with Borrelia burgdorferi. 120 days after tick exposure, 12 dogs were treated with antibiotics for 30 days; 4 control dogs were not treated. "At euthanasia, single tissues of the antibiotic-treated dogs and multiple tissues of all control dogs were Borrelia-positive by polymerase chain reaction."

"Do the data indicate an ongoing persistent infection in these animals or only the presence of DNA remnants of dead Borrelia...? From this study and our previous investigations (20), it appears likely that B. burgdorferi maintains a persistent infection with live organisms albeit at a very low level."

[Diagnosis:] "As demonstrated by the injection of heat-killed B. burgdorferi organisms into the skin of an uninfected animal, DNA of dead organisms was detectable in our hands only for 3 weeks. These results are in concordance with a study in which persistent experimental infection with Treponema pallidum, the spirochetal agent of syphilis, was identified by PCR. Wicher et al. [1998] discovered that DNA of dead Treponema organisms was removed from or degraded within rabbit tissue within 15-30 days after syringe inoculation."

13. Oksi J; Mariamaki M; Nikoskelainen J; Viljanen MK.  
**Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme Borreliosis.**

Annals of Medicine, 31(3):225-32

Of 165 patients treated for disseminated Lyme borreliosis with three months or more of antibiotics (including a minimum of two weeks of ceftriaxone), 32 had treatment failure. At follow-up, 13 patients with clinical relapse were PCR or culture positive (10 PCR positive, 1 culture positive, 2 PCR and culture positive). "In this study, culture or PCR-based evidence for the presence of live spirochetes was obtained in more than 40% of the patients with relapsed disease."

“The treatment caused only temporary relief in the symptoms of the patients.”

“We conclude that the treatment of Lyme borreliosis with appropriate antibiotics for even more than 3 months may not always eradicate the spirochete.”

14. Warner G; O'Connell S; Lawton N.  
**Atypical features in three patients with florid neurological Lyme disease.**

J Neurol Neurosurg Psych, 67(2):275.

“Two [of 3 patients] had new symptoms/signs despite appropriate and adequate treatment; the third a remitting-relapsing course.”

15. Cimperman J; Maraspin V; Lotric-Furlan S; Ruzic-Sabljic E; Strle F.  
**Lyme meningitis: a one-year follow up controlled study.**


[Abstract:] “The results of our study revealed that Lyme meningitis occurs without meningeal signs and is often accompanied by additional borreliosis persisted or occurred for the first time in several patients. They were not infrequent even at the examination performed one year after therapy.” [A total of 36 patients were followed.]

16. Zamponi N; Cardinali C; Tavoni MA; Porfiri L; et al.  
**Chronic neuroborreliosis in infancy.**


[From the abstract:] “Lyme disease is a polymorphic and multisystemic disease caused by Borrelia burgdorferi. Neurological manifestations are found in 10%-50% of cases. We present 2 cases followed for 5 and 6 years of chronic relapsing-relmitting neuroborreliosis.”
17. Kufko IT; Mel'nikov VG; Andreeva EA; Sokolova ZI; Lesniak OM; Beikin IaB.  
Comparative study of results of serological diagnosis of Lyme borreliosis by Indirect immunofluorescence and immunoenzyme analysis. 
Klin Lab Diagn, 3:34-7

“Patients with persistent levels of antibodies to B. burgdorferi, even without clinical signs of infection, are in need of regular check-ups, because the prognostic significance of antibodies to B. burgdorferi is unknown and relapses may occur after months and years.”

18. Treib J; Fernandez A; Haass A; Grauer MT; Holzer G; Woessner R.  
Clinical and serologic follow-up in patients with neuroborreliosis. 
Neurology, Nov;51(5):1489-91

[Abstract:] “The authors performed a clinical and serologic follow-up study after 4.2 +/- 1.2 years in 44 patients with clinical signs of neuroborreliosis and specific intrathecal antibody production. All patients had been treated with ceftriaxone 2 g/day for 10 days. Although neurologic deficits decreased significantly, more than half the patients had unspecific complaints resembling a chronic fatigue syndrome and showed persisting positive immunoglobulin M serum titers for Borrelia in the Western blot analysis.”

19. Hudson BJ; Stewart M; Lennox VA; Fukunaga M; Yabuki M; et al.  
Culture-positive Lyme borreliosis. 

“We report a case of Lyme borreliosis. Culture of skin biopsy was positive for Borrelia garinii, despite repeated prior treatment with antibiotics.”

20. Meier P; Blatz R; Gau M; Spencker FB; Wiedemann P.  
Pars plana vitrectomy in Borrelia burgdorferi endophthalmitis. 
Klin Monatsbl Augenheilkd, 213(6):351-4

“Despite of [sic] intravenous application of ceftriaxon for 14 days panuveitis persisted, and endophthalmitis developed when antibiotic therapy was finished....Despite of a second intravenous ceftriaxon treatment for 14 days we observed a retinal vasculitis in the follow up of 6 months. CONCLUSIONS: Despite intravenous ceftriaxon-therapy borrelia burgdorferi must have survived in the vitreous body.”

21. Straubinger RK; Straubinger AF; Summers BA; Jacobson RH; Erb HN.  
Clinical manifestations, pathogenesis, and effect of antibiotic treatment on Lyme borreliosis in dogs. 
Wien Klin Wochenschr, 110(24):874-81

[Abstract:] “In three separate experiments, B. burgdorferi-infected dogs received antibiotic treatment (amoxicillin; azithromycin; ceftriaxone; doxycycline) for 30 consecutive days. ...Antibiotic treatment prevented or resolved episodes of acute arthritis, but failed to eliminate the bacterium from infected dogs.

“CONCLUSIONS: B. burgdorferi disseminates through tissue by migration following tick inoculation, produces episodes of acute arthritis, and establishes persistent infection. The spirochete survives antibiotic treatment and disease can be reactivated in immunosuppressed animals.”
Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy.

[Persistence:] “Paired SF [synovial fluid] and SM [synovial membrane] specimens and urine samples from four patients with ongoing or recurring Lyme arthritis despite previous antibiotic therapy were investigated. RESULTS: In all four cases, PCR with either primer set was negative in SF and urine, but was positive with at least one primer pair in the SM specimens.”

[Diagnosis:] “CONCLUSIONS: These data suggest that in patients with treatment resistant Lyme arthritis negative PCR results in SF after antibiotic therapy do not rule out the intraarticular persistence of B. burgdorferi DNA. Therefore, in these patients both SF and SM should be analysed for borrelial DNA by PCR as positive results in SM are strongly suggestive of ongoing infection.”

Lyme borreliosis – A review of the late stages and treatment of four cases.

A five-week treatment with doxycycline at a dose of 200 mg daily was prescribed. Fatigue, arthralgia en myalgia seemed to respond positively to the initiated therapy. However, they reappeared two weeks after cessation of doxycycline. ...it was decided to treat with ceftriaxone IM 2 g daily for three weeks. This resulted in a complete resolution of the general symptoms. However, three weeks later arthralgia of the knees and myalgia in both legs recurred. ... Symptoms and signs may improve only temporarily shortly after treatment, but re-emerge within weeks or months.

Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

[From the abstract:] “In specific-pathogen-free dogs experimentally infected with Borrelia burgdorferi by tick exposure, treatment with high doses of amoxicillin or doxycycline for 30 days diminished but failed to eliminate persistent infection. Although joint disease was prevented or cured in five of five amoxicillin- and five of six doxycycline-treated dogs, skin punch biopsies and multiple tissues from necropsy samples remained PCR positive and B. burgdorferi was isolated from one amoxicillin- and two doxycycline-treated dogs following antibiotic treatment. ...[In] dogs that were kept in isolation for 6 months after antibiotic treatment was discontinued, antibody levels began to rise again, presumably in response to proliferation of the surviving pool of spirochetes.”

Two lessons from the canine model of Lyme Disease: migration of Borrelia burgdorferi in tissues and persistence after antibiotic treatment.

“In two studies, antibiotic treatment with amoxicillin or doxycycline for 30 days failed to eliminate persistent infection in 11 dogs. Immediately after treatment, borreliae could not be demonstrated, antibody levels declined, and joint lesions were prevented or cured. Live spirochetes, however, persisted in the tissue of at least three dogs as B. burgdorferi DNA was detected in all 11 treated dogs for up to 6 months after treatment, at which time antibody levels again began to rise.”

[Diagnosis:] “In the dog model, we detected B. burgdorferi reliably in skin but infrequently in blood by culture and polymerase chain reaction (PCR). We found the organism in the synovium of joints but not in synovial fluids, and in meninges but not in cerebrospinal fluid.”
26. Branigan P; Rao J; 1997
Rao J; Gerard H;
Hudson A; Williams W;
Arayssi T; Pando J;
Bayer M; Rothfuss S;
Clayburne G; Sieck M;
Schumacher HR.

PCR evidence for *Borrelia burgdorferi* DNA in synovium in absence of positive serology. Am Coll Rheumatology, 40(9) Suppl, Sept, p.S270

“PCR evidence for *Borrelia* has been identified in synovial biopsies of patients with clinical pictures that had not initially suggested Lyme disease. All [6 PCR-positive] patients were negative for antibodies to *Borrelia* and some were PCR positive in synovium despite previous treatment with antibiotics.”

27. Weber K. 1996

Treatment failure in erythema migrans: a review. Infection, 24:73-5

[From the abstract:] “Patients with erythema migrans can fail to respond to antibiotic therapy. Persistent or recurrent erythema migrans, major sequelae such as meningitis and arthritis, survival of *Borrelia burgdorferi* and significant and persistent increase of antibody titres against *B. burgdorferi* after antibiotic therapy are strong indications of a treatment failure. Most, if not all, antibiotics used so far have been associated with a treatment failure in patients with erythema migrans.”

28. Nanagara R; 1996
Duray PH;
Schumacher HR Jr.


[From the abstract:] “Electron microscopy [both EM and IEM were used] adds further evidence for persistence of spirochetal antigens in the joint in chronic Lyme disease. Locations of spirochetes or spirochetal antigens both intracellularly and extracellularly in deep synovial connective tissue as reported here suggest sites at which spirochaetes may elude host immune response and antibiotic treatment.”

[From the article:] “If spirochetes are already sequestered in tissue that is inaccessible to antibiotics such as in the fibrinous and collagen tissue or within fibroblasts, high-dose parenteral antibiotics, or combination therapies with long duration may be needed to kill the living spirochetes.” (p.1032)

29. Mursic VP; 1996
Wanner G; Reinhardt S;
Wilske B; Busch U;
Marget W.

Formation and cultivation of *Borrelia burgdorferi* spheroplast L-form variants. Infection, 24(3):218-26

[Persistence:] “…clinical persistence of *Borrelia burgdorferi* in patients with active Lyme borreliosis occurs despite obviously adequate antibiotic therapy…” “The persistence of Bb even after therapy with antibiotics has been demonstrated in cerebrospinal fluid (CSF), in skin, iris, heart and joint biopsies.”

[Cysts:] In vitro investigation of morphological variants of *B. burgdorferi*, in an effort to explain the clinical persistence of active Lyme borreliosis despite antibiotic therapy. The authors suggest that these atypical forms may allow *Borrelia* to survive antibiotic treatment.

30. Luft BJ; 1996
Dattwyler RJ; Johnson RC;
Luger SW; Bosler EM;
Rahn DW; et al.

Azithromycin compared with amoxicillin in the treatment of erythema migrans. Annals Internal Med, 124(9):785-91

A double-blind, randomized, controlled trial.

“Fifty-seven percent of patients who had relapse were seronegative at the time of relapse.”
31. Bayer ME; Zhang L; 1996
Bayer MH.

**Borrelia burgdorferi DNA in the urine of treated patients with chronic Lyme disease symptoms**

*Infection*, 24 No.5

A PCR study of 97 cases.

*The urine of 74.2% of patients previously treated with antibiotics for Lyme disease was found to be positive for B. burgdorferi DNA using PCR testing. All patients (n=97) had prior documented EM rash and had received a minimum of 3 weeks to 2 months oral or intravenous antibiotics. In 4 patients, PCR results were temporarily negative after treatment, but became positive again 4-6 weeks later. All patients suffered "continuing, often gradually worsening Lyme disease-like symptoms. ...it seems to be characteristic for most of the patients in our study that, after antibiotic-free periods of a few months, they had again become increasingly ill with neurological and arthritic symptoms, so that treatment had been resumed."*

32. Aberer E; Kersten A; 1996
Klade H; Poitschek C; Jurecka W.

**Heterogeneity of Borrelia burgdorferi in the skin.**


"Neuralgias arising 6 months after ECM in spite of antibiotic therapy were evident in a seronegative patient who showed perineural rod-like borrelia structures."

33. Oksi J; Kalimo H; 1996
Marttila RJ; Marjamaki M; Sonninen P; et al.

**Inflammatory brain changes in Lyme borreliosis. A report on three patients and review of literature.**

*Brain*, Dec;119 ( Pt 6):2143-54

"In one of the six analysed brain tissue specimens [from a patient who had received more than six months of antibiotic treatment prior to death, including two 3-week courses of IV ceftriaxone], B. burgdorferi DNA was detected by PCR."

34. Valesova H; Mailer J; Havlik J; Hulinska D; Hercogova J.

1996 **Long-term results in patients with Lyme arthritis following treatment with ceftriaxone.**


"Long term clinical results in 26 patients at 36 months were complete response or marked improvement in 19, relapse in six and new manifestations in four of the cases, respectively."

35. Preac Mursic V; 1996
Margit W; Busch U; Pleterski Rigler D; Hagl S.

**Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.**


[Persistence:] "...the persistence of B. burgdorferi s.l. and clinical recurrences in patients despite seemingly adequate antibiotic treatment is described.” ... [Seronegativity:] “The patients had clinical disease with or without diagnostic antibody titers to B. burgdorferi.”

36. Girschick HJ; Huppertz Hl; Rüssman H; Krenn V; Karch H.

1996 **Intracellular persistence of Borrelia burgdorferi in human synovial cells.**

*Rheumatol Int*, 16(3):125-32.

[From the abstract:] “Treatment with ceftriaxone eradicated extracellular Borrelia burgdorferi, but spirochetes were reisolated after lysis of the synovial cells. Borrelia burgdorferi persisted inside synovial cells for at least 8 weeks. These data suggested that Borrelia burgdorferi might be able to persist within resident joint cells in vivo.”
37. Seronegative chronic relapsing neuroborreliosis. Lawrence C; Lipton RB; Lowy FD; Coyle PK. 1995 European Neurology, 35(2):113-7

[From the abstract:] This article reports a Lyme disease patient “who experienced repeated neurologic relapses despite aggressive antibiotic therapy.” The patient was seronegative. “Although the patient never had detectable free antibodies to B. burgdorferi in serum or spinal fluid, the CSF was positive on multiple occasions for complexed anti-B. burgdorferi antibodies, B. burgdorferi nucleic acids and free antigen.”

[From the article:] “Before her 6th hospital admission this patient had received four courses of ceftriaxone, one of cefotaxime and two of doxycycline (of 19 and 8 weeks). Increasing right hemiparesis and dyspnea with right intercostal muscle weakness prompted her 6th admission to the hospital. Following intravenous ceftriaxone for 2 weeks, it was decided to place the patient on long-term therapy [22 months] with clarithromycin. Although there is no information on the penetration of clarithromycin into the CNS, it achieves high concentrations within macrophages [18] a known sanctuary for the Bb spirochete [19]. The clinical response to clarithromycin in this patient has now been sustained for over 22 months.”

“...Survival of Bb in humans despite aggressive antibiotic therapy has been previously reported [2,22]. We believe this to be an example of a patient with chronic relapsing Bb infection. It is important to evaluate unusual patients like this thoroughly in order to determine the effectiveness of prolonged oral antibiotics as a therapeutic option.”


“...a 1-month course of oral antibiotics may not always eradicate viable spirochetes.”


[From the abstract:] “The authors report a case of fatal neuropsychiatric Lyme disease (LD) that was expressed clinically by progressive frontal lobe dementia and pathologically by severe subcortical degeneration. Antibiotic treatment resulted in transient improvement, but the patient relapsed after the antibiotics were discontinued. LD [Lyme disease] must be considered even in cases with purely psychiatric presentation, and prolonged antibiotic therapy may be necessary.”


A Finnish physician’s account of his experiences that beginning with a tick bite in Vancouver in 1987. Dr. Vartiovaara resigned from his position with the Finnish Medical Journal in 1992, due to disabilities caused by Lyme disease.

[Persistence:] “After that [a positive result on a T-cell proliferation test at Stony Brook Hospital] I had two months' heavy treatment with oral doxycycline 300mg a day. I was a little better after it, but only for about two months. Then it started all over again, and got worse. ...We sent blood and spinal fluid to Dr. Oksi and they turned out to be positive [by PCR]–in other words, the spirochaete was still alive in my body after six years, despite the antibiotics.” Dr. Vartiovaara was then treated aggressively with a combination of antibiotics, including four weeks of ceftriaxone, for six months. Some time after the cessation of treatment however, he found that “My symptoms are on the move again.”

[Diagnosis:] “What should be done when a patient has the typical Lyme disease history but negative serology? This is still a hot question especially in the USA. My strong opinion is that oral antibiotics should be given in such cases. Ordinary laboratory tests cannot be relied upon and the PCR is too expensive for routine use. When the whole picture leans towards Lyme borreliosis it is both ethically and medically right to treat.” (p.844)
41. Ferris J; 1995
Lyme borreliosis. [Letter]  
Lancet, Vol 345: 1436-37

“Our patient received during 2 years seven short-term antibiotic treatments, achieving transitory improvements. Nonetheless, his condition greatly deteriorated. In October, 1993, he started a different antibiotic regimen (ceftriaxone, 2 g per day intravenously for 12 months, oral roxithromycin 150 mg per day for 2 months, and oral ciprofloxacin, 500 mg per 12 hours for 2 months). After ceftriaxone he has continued with oral minocycline, 100 mg per 12 hours for 7 months. His quality of life has greatly improved and the treatment is more tolerable than the borreliosis.”

“We add, however, in accord with the advice of others that antibiotics should be continued in the long term, until we achieve cure or delay the progression of the disease.”

42. Wahlberg P; 1994
Treatment of late Lyme borreliosis.  
Journal of Infection, 3:255-61

[From the abstract:] “Short periods of treatment were not generally effective.”

[From the article:] “Symptoms and signs often improve temporarily shortly after treatment but reappear within weeks or months. ...To conclude, we have shown that long-term treatments beginning with intravenous ceftriaxone and continuing with amoxycillin plus probenecid or with cephalaxin were useful in the treatment of late Lyme borreliosis.” (pp. 260-1)

43. Malawista SE; 1994
Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment.  
J Infectious Dis, 170:1312-16

The mice receiving antibiotic treatment in this study were given ceftriaxone.

[Persistence:] 2 out of 5 mice tested 60 days after treatment were found to be positive on culture; 1 of these mice was also positive by PCR. The authors speculate that this could be due to: (a) reinfection (which they consider “highly unlikely”), (b) contamination, or (c) the “resurgence of spirochetes in animals not completely sterilized by antibiotics. This last possibility will bear further scrutiny because late recurrences of Lyme disease without obvious reinfection may occur in humans.”

[Diagnosis:] Positive PCR results were found to suggest active infection. "Unless some patients with Lyme disease have a defect in their ability to degrade spirochetal DNA, these results suggest that persisting PCR positivity indicates persisting infection.”

44. Bradley JF; 1994
The persistence of spirochetal nucleic acids in active Lyme arthritis.  
Annals Internal Med, 120(6):487-9

“Our results show the intra-articular persistence of B. burgdorferi nucleic acids in Lyme arthritis and suggest that persistent organisms and their components are important in maintaining ongoing immune and inflammatory processes even among some antibiotic-treated patients. Further studies are needed to determine the microbiologic state of these organisms and their therapeutic and prognostic implications.” (p.489)

45. Asch ES; Bujak D; 1994
Lyme disease: an infectious and postinfectious syndrome.  
J Rheumatology, 3:454-61

[From the abstract:] “Patients were seen at a mean of 3.2 years after initial treatment. A history of relapse with major organ involvement had occurred in 28% and a history of reinfection in 18%. Anti-Borrelia antibodies, initially present in all patients, were still positive in 32%. At followup, 82 (38%) patients were asymptomatic and clinically active Lyme disease was found in 19 (9%). Persistent symptoms of arthralgia, arthritis, cardiac or neurologic involvement with or without fatigue were present in 114 (53%) patients.”
...18 patients (8%) received intravenous antibiotics (penicillin in 14 and ceftriaxone in 4) as initial therapy and 6 (33%) of these patients relapsed. Subsequent courses of antibiotic therapy were used in 51 (24%) patients. Many received repeated courses of antibiotic therapy for disease relapse and had full or partial response to this treatment.

The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study.

“Ten of the 38 patients with Lyme disease reported relapses within 1 year of treatment... and had had repeated antibiotic treatment (5 patients with intravenous ceftriaxone). Patient 4, in addition, had had second degree atioventricular block with acute Lyme disease that resolved with penicillin treatment. Her irregular rhythm recurred 2 years later, resolved temporarily with ceftriaxone treatment, but progressed to complete heart block requiring a pacemaker. Patient 12... was treated with 2 weeks of parenteral penicillin. She later developed a progressive speech disorder, bradykinesia, and abnormal ocular motor function. Magnetic resonance imaging of the brain showed scattered white matter lesions in the hemispheres and pons... she was re-treated with 2 weeks of parenteral ceftriaxone in 1989 that had no effect on her neurologic symptoms. During the time of observation, this patient died. At autopsy... [using] Dieterle silver stain, a spirochete was present in the cortex and another was exterior to a leptomeningeal vessel.”

Treatment of late Lyme disease: a challenge to accept.

“The patient] received 2 g of ceftriaxone daily for 4 weeks. Marked early clinical improvement was observed and continued for 3 weeks after therapy was discontinued. He received 6 additional courses of intravenous antibiotics for 3 to 5 weeks’ duration (penicillin, doxycycline [two courses], and ceftriaxone [three courses]), and 1 oral antibiotic (azithromycin). His general condition improved, but each antibiotic course was followed by a relapse.”

First isolation of Borrelia burgdorferi from an iris biopsy.

“The persistence of Borrelia burgdorferi in six patients is described. Borrelia burgdorferi has been cultivated from iris biopsy, skin biopsy, and cerebrospinal fluid also after antibiotic therapy for Lyme borreliosis. Lyme Serology: IgG antibodies to B. burgdorferi were positive, IgM negative in four patients; in two patients both IgM and IgG were negative. Antibiotic therapy may abrogate the antibody response to the infection as shown by our results. Patients may have subclinical or clinical disease without diagnostic antibody titers. Persistence of B. burgdorferi cannot be excluded when the serum is negative for antibodies against it.”

Invasion of human skin fibroblasts by the Lyme disease spirochetes, Borrelia burgdorferi.

This study found that B. burgdorferi spirochetes can survive antibiotic treatment through intracellular sequestration within fibroblasts. “In these experiments, we demonstrated that fibroblasts and keratinocytes were able to protect B. burgdorferi from the action of this B-lactam antibiotic [ceftriaxone] even at antibiotic concentrations > or = 10 times the MBC of the antibiotic. The protective effect was sustained for < or = 14 days and required viable fibroblast monolayers... We have demonstrated the presence of intracellular B. burgdorferi within HF [human fibroblasts] using laser scanning confocal microscopy... The observation of viable spirochetes within fibroblasts coupled to protection of B. burgdorferi from extracellular microbicidal antibiotics by fibroblasts [19] suggests that B. burgdorferi may be among the small number of bacteria that can cause chronic infection by localizing within host cells where they remain sequestered from some antimicrobial agents and the host humoral immune response.”
Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis.

[Persistence:] “Repeated antibiotic treatment [6 weeks oral doxycycline, 2 weeks intravenous ceftriaxone, 2 weeks combination of oral roxithromycin/sulfamethoxazole/trimethoprim] was necessary to stop the progression of disease, but obviously did not completely eliminate B burgdorferi from all sites of infection. This was confirmed by the culture of viable B burgdorferi from a ligament sample obtained surgically. [The cultured bacteria were identified as B. burgdorferi by reactions with specific immune sera and monoclonal antibodies, and by polymerase chain reaction amplification and Southern blot hybridization techniques.]

...These data indicate that vital B burgdorferi persisted (a) despite several courses of antibiotic therapy, (b) even when clinical symptoms subsided, and (c) even when no humoral immune response was detectable by ELISA or by IF.” (p. 1625)

[Treatment:] “The hypothesis of evasion [to explain the survival of Bb] supports the use of more aggressive therapy as described in recent reports (19), in which 3-4 weeks of intravenous antibiotics was suggested as first-line treatment when systemic manifestations develop, such as the choroiditis in our patient.” (p.1626)

[Irtracellular:] “Electron microscopy of the ligament revealed spirochetes situated between collagen fibers or associated with fibroblasts, deeply invaginating these cells.” (p.1625)

[Diagnosis:] [From the abstract:] “The initially significant immune system activation was followed by a loss of the specific humoral immune response and a decrease in the cellular immune response to B burgdorferi over the course of the disease.” [From the article:] “Interestingly, the cellular immune responses were also directed against the surface protein OspA during each recurrence of clinical symptoms, even though anti-OspA antibodies were not detectable by immunoblot.” (p.1625)
55. Georgilis K; Peacocke M; Klempner MS. 1992
Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro.

[From the abstract:] “The Lyme disease spirochete, Borrelia burgdorferi, can be recovered long after initial infection, even from antibiotic-treated patients, indicating that it resists eradication by host defense mechanisms and antibiotics. ...Human foreskin fibroblasts protected B. burgdorferi from the lethal action of a 2-day exposure to ceftriaxone at 1 microgram/mL, 10-20 x MBC. In the absence of fibroblasts, the organisms did not survive. ...Fibroblasts protected B. burgdorferi for at least 14 days of exposure to ceftriaxone. Mouse keratinocytes, HEP-2 cells, and Vero cells but not Caco-2 cells showed the same protective effect. Thus, several eukaryotic cell types provide the Lyme disease spirochete with a protective environment contributing to its long-term survival.”

[From the article:] “An intracellular site of survival would provide protection, since many of the antibiotics are much less concentrated in the cells than in extracellular spaces. ...Possibly fibroblasts and keratinocytes are the initial sites of this intracellular survival. This is especially relevant in that the first contact between the spirochete and the host in Lyme disease occurs in the skin.” (p.443)

56. Cooke WD; Peacocke M; Klempner MS. 1992
Complications of Lyme borreliosis.

“...we recalled 32 patients with Lyme disease from a primary care practice a mean of 16 months after treatment... Nine of the 32 patients had persistent or recurrent symptoms, and ELISA and immunoblot were not helpful for identifying these nine patients.”

57. Feder HM Jr; Gerber MA; Luger SW; Ryan RW. 1992
Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease.

[From the abstract:] “...we recalled 32 patients with Lyme disease from a primary care practice a mean of 16 months after treatment... Nine of the 32 patients had persistent or recurrent symptoms, and ELISA and immunoblot were not helpful for identifying these nine patients.”

58. Dinerman H; Dattwyler RJ. 1992
Lyme disease associated with fibromyalgia.

“An intracellular site of survival would provide protection, since many of the antibiotics are much less concentrated in the cells than in extracellular spaces. ...Possibly fibroblasts and keratinocytes are the initial sites of this intracellular survival. This is especially relevant in that the first contact between the spirochete and the host in Lyme disease occurs in the skin.” (p.443)
59. Pfister HW; Preac-Mursic V; Wilske B; Schielke E; Sorgel F; Einhaupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Inf Dis, Feb;163(2):311-8

33 patients with Lyme neuroborreliosis were treated for 10 days with either IV ceftriaxone or IV cefotaxime. Follow-up examinations were conducted after a mean of 8.1 months. 10 of 27 patients examined were symptomatic at follow-up and borreliae persisted in the CSF of one patient. The authors conclude that "a prolongation of therapy may be necessary."

60. Agger W; Case KL; Bryant GL; Callister SM. Lyme disease: clinical features, classification, and epidemiology in the upper midwest. Medicine (Baltimore) Mar;70(2):83-90

"Despite longer and more frequent parenteral therapy, late Lyme disease frequently required retreatment, owing to poor clinical response (p less than .05)."


"Active cases of Lyme disease may show clinical relapse following antibiotic therapy. The latency and relapse phenomena suggest that the Lyme disease spirochete is capable of survival in the host for prolonged periods of time. We studied 63 patients with erythema migrans, the pathognomonic cutaneous lesion of Lyme borreliosis, and examined in vitro cultures of biopsies from the active edge of the erythematous patch. Sixteen biopsies yielded spirochetes after prolonged incubations of up to 10.5 months, suggesting that Borrelia burgdorferi may be very slow to divide in certain situations. Some patients with Lyme borreliosis may require more than the currently recommended two to three week course of antibiotic therapy to eradicate strains of the spirochete which grow slowly."

62. Logigian EL; Kaplan RF; Steere AC. Chronic neurologic manifestations of Lyme disease. NEJM, Nov 22; 323(21):1438-44

[From the abstract:] "Six months after a two-week course of intravenous ceftriaxone (2 g daily), 17 patients (63 percent) had improvement, 6 (22 percent) had improvement but then relapsed, and 4 (15 percent) had no change in their condition."

[From the article:] "Discussion.....These chronic neurologic abnormalities began months to years after the onset of infection, sometimes after long periods of latency, as in neurosyphilis.....The typical response of our patients to antibiotic therapy supports the role of spirochetal infection in the pathogenesis of each of the syndromes described here......The likely reason for relapse is failure to eradicate the spirochete.......This is reminiscent of far advanced neurosyphilis....... This last article is one of many studies that show continuing symptoms are most likely due to persistence of the spirochete."

63. Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Medicine, 88:577-581

[Relapse:] "Nine patients were seen who had a preceding history of Lyme disease and previous successful therapy, but the nonspecific symptoms had returned."

64. Nadelman RB; Pavia CS; Magnarelli LA; Wormser GP. Isolation of Borrelia burgdorferi from the blood of seven patients with Lyme disease. Am J Medicine, 88:21-26

[Persistent Symptoms:] "Five of seven patients remained symptomatic at a median of four months after treatment..."

[Treatment/Relapse:] "As in other spirochetal infections, antibiotic therapy is most effective early in the illness. ...
TREATMENT PROBLEMS...Late Disease: Not all patients with neurologic manifestations or with arthritis respond to oral or intravenous antibiotic therapy (19), and in many of these individuals, retreatment may be necessary. Retreatment is also appropriate in individuals who relapse, for example, with recurrent arthritis. ...Late in the illness, cases refractory to antibiotic therapy may be encountered."

66. Dieterle L; Kubina FG; 1989 Neuro-borreliosis or intervertebral disk prolapse? Staudacher T; Budingen HJ.

"Despite antibiotic treatment (usually 10 mega U penicillin three times daily) six patients had a recurrence by April, 1989, treated with penicillin again or with twice daily 100 mg doxycycline or 2 g ceftriaxon."


[From the abstract:] "We conclude that early stage of the disease as well as chronic Lyme disease with persistence of B. burgdorferi after antibiotic therapy cannot be excluded when the serum is negative for antibodies against B. burgdorferi."

[Persistence:] "However, some patients later developed symptoms of the disease despite antibiotic treatment (9-11). Because of these observations it has become questionable if a definite eradication of B. burgdorferi with antibiotics is possible." (p.357) ...
"The central nervous system invasion by spirochetes and a persistence of Treponema pallidum after penicillin G therapy is common in neurosyphilis (22,23)." (p.358)

[Treatment:] "In view of the hitherto failure of treatment, low CSF concentration of penicillin G, survival of B. burgdorferi in patients treated with antibiotics, the moderate penicillin G susceptibility of the organism and unpredictable progression of the disease, it seems appropriate to treat patients with substantially larger doses of antibiotics and/or longer than is provided in present treatment regimens." (p.358)

[Seronegativity:] "As shown, negative antibody-titers do not provide evidence for successful therapy; antibody-titers may become negative despite persistence of B. burgdorferi." (p.358)

68. Kohler J; 1989 High-dose intravenous penicillin G does not prevent further progression in early neurological manifestation of Lyme borreliosis.

[From the abstract:] "We report two cases of Lyme borreliosis (LB) with erythema migrans (EM) and simultaneous meningopolyneuritis... EM and pain disappeared completely under high-dose penicillin G therapy within few a days. Pathological findings in CSF improved. Nevertheless, during and after therapy, neurological signs of LB developed: cranial nerve palsies as well as paresis of extremity muscles with radicular distribution."
1. Spirochetal antigens and lymphoid cell surface markers in Lyme synovium and tonsillar lymphoid tissue. 

[Persistence:] "Synovial tissue was obtained from 12 patients with Lyme disease who underwent arthroscopic synovectomy between 1984 and 1986. ...All patients had received antibiotic therapy and nonsteroidal antiinflammatory drugs (NSAIDs) prior to arthroscopic synovectomy. (p.488) ..."Using monoclonal antibodies to the 31- or 41-kd polypeptides of B burgdorferi, a few spirochetes and globular antigen deposits were seen in and around normal or injured blood vessels in areas of lymphocytic infiltration, in 6 of the 12 patients (Figure 4)."

"Similarly [as in tertiary syphilis or tuberculoid leprosy], the antigenic stimulus in Lyme arthritis would appear to be a small number of live spirochetes, demonstrated here by monoclonal antibodies, which may persist in the synovial lesion for years."


[From the abstract:] "We studied 17 patients who had presented with acute Lyme disease and received prompt treatment with oral antibiotics, but in whom chronic Lyme disease subsequently developed."

3. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. 

"Despite clinical resolution of paralysis, subsequent arthritic complication occurred. To our knowledge, this is the first report of the successful isolation of B. burgdorferi from synovial fluid and the subsequent propagation through serial passage. This positive culture strongly suggests that the spirochetes were not eradicated by the initial antimicrobial regimens [12 days amoxicillin-clavulanate followed by two weeks of doxycycline, 200 mg/d]. ...Other possible explanations of treatment failure, such as insufficient patient compliance or reinfection by B. burgdorferi, were excluded by close medical and parental supervision. The patient was subsequently treated with 14 days intravenous ceftriaxone. Her arthritic symptoms resolved, and she remained symptom-free during an 11-month follow-up period."

4. Treatment of erythema chronicum migrans of Lyme disease. 

"Two of 80 patients with a minor form of the illness and 17 of 81 patients with a major form of the illness required retreatment."


"We now demonstrate B. burgdorferi in the brain and liver of a newborn whose mother had been treated with oral penicillin for LB [Lyme borreliosis] during the first trimester of pregnancy. ...The death of the newborn was probably due to a respiratory failure as a consequence of perinatal brain damage."

6. Failure of tetracycline therapy in early Lyme disease. 

"We describe the clinical courses of 5 patients with Lyme disease who developed significant late complications, despite receiving tetracycline early in the course of their illness. All 5 patients had been treated for erythema chronicum migrans with a course of tetracycline that met or exceeded current recommendations."
"Fourteen of sixty-one patients with a major form of the illness required retreatment, and five developed posttreatment late manifestations of Lyme disease consisting of Bell’s palsy and persistent joint pain."

[From the abstract:] "However, with all three antibiotic agents nearly half of the patients had minor late symptoms such as headache, musculoskeletal pain, and lethargy. These complications correlated significantly with the initial severity of illness."

"We remain skeptical that antibiotic therapy helps... Eight of our patients received penicillin, erythromycin, or cephalexin before entering the study because of the skin lesion. In one of them, the lesion persisted for 2 months despite therapy, longer than in any of the other study patients, and seven of the eight patients still developed joint, neurologic, or cardiac abnormalities."

“Particularly puzzling has been the observation that organisms are extremely difficult to find in infected tissue, using either microbiologic or morphologic techniques. However, in many instances continued infection appears to be essential for symptoms to persist, no matter how small the number of organisms, as antimicrobial therapy is generally followed by clinical improvement.”

John J. Halperin, MD and Melvin P. Heyes, PhD.
Neuroactive kynurenines in Lyme borreliosis.